Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells

BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are elevated in the circulation of patients with glioblastoma (GBM), present in tumor tissue, and associated with poor prognosis. While low-dose chemotherapy reduces MDSCs in preclinical models, the use of this strategy to reduce MDSCs in GBM pati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Autores principales: Peereboom, David M., Alban, Tyler J., Grabowski, Matthew M., Alvarado, Alvaro G., Otvos, Balint, Bayik, Defne, Roversi, Gustavo, McGraw, Mary, Huang, Pengjing, Mohammadi, Alireza M., Kornblum, Harley I., Radivoyevitch, Tomas, Ahluwalia, Manmeet S., Vogelbaum, Michael A., Lathia, Justin D.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2019
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948860/
https://ncbi.nlm.nih.gov/pubmed/31600167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.130748
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares